Introduction
In the peripheral nervous system (PNS), Schwann cells (SCs) serve as 'first responders' to injury. Distal to the injury site, SCs dedifferentiate, downregulating myelin gene expression and considerably altering their mRNA transcriptome. This process involves (i) upregulation of pathways that support survival in the challenging microenvironment of the injured PNS; (ii) activation of the transcription factor c-Jun; (iii) orchestration of the inflammatory response; and (iv) secretion of growth factors and structural proteins that guide and support axonal regeneration [1] [2] [3] . Activated SCs also participate in the first phase of myelin degradation [1, 3, 4] . Collectively, these changes are referred to as 'activation of the SC repair program' [3] . Considerable work has been carried out to determine the changes in cell-signaling and gene expression that drive these robust and important changes in the SC phenotype. However, receptors that sense nerve injury remain unidentified.
LDL receptor-related protein 1 (LRP1) is a type I transmembrane receptor with endocytic and cell-signaling activity, which is expressed by SCs selectively in nerve injury and promotes many of the changes observed in SCs in the activated repair program [5] [6] [7] [8] . When presented with specific ligands, LRP1 activates cell-signaling pathways in SCs, which support SC survival, even in the absence of axonal contact [5, 9] . By regulating ERK1/2, Rac1, and RhoA, LRP1 promotes SC migration [6] [7] [8] . Furthermore, LRP1 functions in the phagocytosis of debris that may accumulate in PNS injury [10] . Finally, by activating ERK1/2, LRP1 ligands induce expression of MCP-1/CCL2, a potent chemoattractant for inflammatory cells in PNS injury [11] . These activities position LRP1 favorably to function as a key receptor in activation of the SC repair program.
Unlike most other receptors, LRP1 binds over 60 ligands that are both structurally and functionally diverse [12] . LRP1 ligands that have been identified by proteomics screens include protein components of degenerated myelin and intracellular proteins that may be released into the extracellular spaces following tissue injury [13] . We hypothesized that the broad ligand-binding capacity of LRP1 may allow this receptor to survey the cellular microenvironment for evidence of injury and trigger early cell-signaling responses, required for activation of the SC repair program.
Here, we define LRP1 as an activator of the global transcription factor, c-Jun, which plays a central role in activation of the SC repair program. We show that different LRP1 ligands, including tissue plasminogen activator (tPA) and a glutathione S-transferase fusion protein that includes the hemopexin domain of matrix metalloproteinase-9 (PEX) [7] , activate c-Jun in primary cultures of rat SCs in vitro. This response was blocked by an LRP1 signaling antagonist, Receptor-associated protein (RAP). LRP1 showed equivalent activities in studies with human SCs. When LRP1 ligands were injected into rat sciatic nerves, 24 h after crush injury, c-Jun was robustly activated in vivo. Finally, we have shown for the first time that LRP1 is expressed by human SCs in culture and initiates c-Jun activation. The function of LRP1 as a cell-signaling receptor, therefore, is conserved in human and rat SCs. Our results suggest that LRP1 may function as a key SC injury detection receptor and play a pivotal role in activating the SC repair program in PNS injury.
Materials and methods

Proteins and reagents
Nonenzymatic, noncleavable human tPA was purchased from Molecular Innovations (Novi, Michigan, USA). RAP and PEX were expressed as glutathione S-transferase fusion proteins and purified as described previously [7, 14] . Proteins expressed in bacteria were subjected to urea treatment, followed by dialysis and Detoxi-Gel endotoxin-removing columns (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The following antibodies and dilutions were used for immunoblotting: phospho-c-Jun (#9261, 1 : 1000), total c-Jun (#9165, 1 : 1000), phospho-ERK1/2 (#9101, 1 : 1000), total ERK1/2 (#9102, 1 : 1000), and horseradish peroxidase (HRP)linked antirabbit IgG (#7074, 1 : 2000). These antibodies were purchased from Cell Signaling Technologies (Danvers, Massachusetts, USA). Antibodies targeting β-actin (A5316, 1 : 5000) and the C-terminal light chain of LRP1 (L2170, 1 : 1000) were from Sigma-Aldrich (St. Louis, Missouri, USA). HRP-linked antimouse IgG (#1 706 516, 1 : 5000) was from BioRad (Hercules, California, USA). Immunofluorescence (IF) microscopy was performed using an antibody that detects myelin protein P0 (AB9352, 1 : 250) from Millipore (Billerica, Massachusetts, USA), phosphorylated c-Jun (#9261, 1 : 100) from Cell Signaling Technologies, Alexa Fluor 568-conjugated antirabbit IgG (A10042, 1 : 300) from Thermo Fisher Scientific, and Alexa Fluor 488-conjugated antichicken IgG (703-545-155, 1 : 300) from Jackson ImmunoResearch Laboratories Inc. (West Grove, Pennsylvania, USA).
Cell culture
Rat SCs were isolated from sciatic nerves extracted from 1-day-old Sprague Dawley rats and purified with the Thy1.1 antibody (M-7898; Sigma-Aldrich) and rabbit complement (S7764; Sigma-Aldrich) as described previously [5] . Primary cultures of more than 95% rat SCs [5] were maintained in complete medium consisting of Dulbecco's Modified Eagle Medium (11885; Thermo Fisher Scientific) supplemented with 10% heat-inactivated FBS (SH30080.03; Thermo Fisher Scientific), 100 U/ml penicillin, 100 μg/ml streptomycin, 21 μg/ml bovine pituitary extract (CC-4009; Lonza, Walkersville, Maryland, USA), and 4 μM forskolin (344 270; Millipore) at 37°C in a humidified atmosphere with 5% CO 2 . Primary cultures of human SCs, isolated from human spinal nerve, were purchased from ScienCell Research Laboratories (#1700; Carlsbad, California, USA) and maintained in the manufacturer's SC medium (#1701) at 37°C with 5% CO 2 . Experiments were conducted with cells that were passaged no more than seven times.
Activation of c-Jun in vitro
SCs were seeded into six-well plates at a density of 1-3 × 10 5 cells/well and grown until 70-80% confluent. Cultures were then washed with and maintained in serum-free medium (Ultraculture, 12-725F; Thermo Fisher Scientific) supplemented with 2 mM L-glutamine (25030-081; Thermo Fisher Scientific) for a total of 35 min (rat SCs) or 45 min (human SCs). LRP1 ligands (100 nM MMP-9-PEX or 12 nM tPA) were added as indicated. In some studies, the LRP1 cell-signaling antagonist, RAP (300 nM), was added 20 min before the agonistic ligands. Cells were washed in ice-cold 20 mM sodium phosphate, 150 mM NaCl, pH 7.4 (PBS), and extracted in RIPA buffer (1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate) with protease inhibitors (Complete, mini-EDTA free; Roche, Indianapolis, Indiana, USA). Protein concentrations of cell extracts were determined using a bicinchoninic acid assay (23225; Thermo Fisher Scientific) and equal amounts of protein (5-20 µg) were subjected to immunoblotting.
Immunoblotting
Protein extracts were subjected to SDS-PAGE (10%) and transferred to nitrocellulose membranes using the Mini-Trans-Blot system (BioRad, Hercules, California, USA). Membranes were blocked with 5% nonfat dry milk (#170-6404; BioRad) in 10 mM Tris/HCl, 150 mM NaCl, pH 7.5, 0.1% Tween 20 (TBST) for 1 h at room temperature. Primary antibodies diluted in 5% BSA/TBST were incubated overnight at 4°C. Membranes were washed with TBST and incubated with secondary HRP-coupled antibodies in TBST with 5% nonfat dry milk for 1 h at room temperature. Protein bands were visualized using Pierce ECL 2 substrate (#80196; Fisher Scientific) and radiographic films on a Kodak X-Omat 2000A and digitized using a CanoScan 5600F (Canon, Lake Success, New York, USA) scanner. Membranes were reprobed with additional antibodies after incubation in stripping buffer (62 mM Tris/HCl, pH 6.8, 2% SDS, 100 mM β-mercaptoethanol) for 30 min at 50°C, followed by extensive washes with TBST.
Activation of c-Jun in SCs by LRP1 ligands in vivo
All animal procedures were performed according to protocols approved by the University of California, San Diego Committee on Animal Research, and conform to the NIH Guidelines for Animal Use. Sprague-Dawley rats (200 g) from Harlan Laboratories (San Diego, California, USA) were housed in pairs with 12-h-light/dark cycles and adlibitum access to food and water. Surgeries were performed as described previously [15] . Briefly, animals were anesthetized with 5% isoflurane (Fluriso; VetOne, Boise, Idaho, USA) and anesthesia was maintained at 3% isoflurane. Using a sterile technique, the right sciatic nerve was exposed at the mid-thigh level by separating the muscle layers and crushed for 15 s with a flat forceps. The muscle layer was closed with silk sutures and the skin with small surgical staples. Rats were anesthetized 24 h after injury and 2 µl of LRP1 ligand (12 µM tPA or 20 µM PEX) or vehicle (PBS) was injected into the sciatic nerve at the crush injury site. After 15 min, the sciatic nerve was collected distal to the crush injury site (0-3 mm). The contralateral nerve was collected as a control. Tissue samples were extracted in RIPA buffer with subsequent sonication (500 Sonic Dismembrator; Fisher Scientific). Protein concentrations were determined and immunoblotting was performed as described above. For IF microscopy studies, sciatic nerve tissue samples were rinsed with PBS, embedded in Tissue-Tek optimum cutting temperature compound (25608-930, VWR, Visalia, California, USA), and fresh-frozen on dry ice.
Immunofluorescence microscopy
Fresh-frozen nerve tissues were sectioned (transversal, 10 µm thick) on a cryostat (Leica, Wetzlar, Germany) and transferred to microscopy slides (VWR Superfrost Plus Micro Slide, 48311-703). Tissue sections were washed with PBS and blocked in 5% BSA/PBS with 0.3% Triton X-100 for 30 min at room temperature. Primary antibodies diluted in blocking solution were incubated overnight at 4°C. Slides were washed with PBS and incubated with fluorescent secondary antibodies in blocking solution for 1 h at room temperature. Sections were sealed with mounting medium (ProLong Gold antifade reagent with DAPI, P36935; Thermo Fisher Scientific) and dried overnight. Images (800 × 800 pixel, 12 bits) were acquired using an Olympus FV1000 confocal microscope (Waltham, Massachusetts, USA) with an oil-immersion objective (60 × , 1.42 NA) and analyzed using ImageJ (NIH, Bethesda, Maryland, USA).
Statistical analysis
Data are represented as mean SD. Densitometry was performed with ImageJ (version 1.50i) and statistical comparisons were performed by one-way analysis of variance and Tukey's post-hoc analysis in Prism (version 6; GraphPad).
Results
LRP1 activates c-Jun in rat SCs in vitro
Rat SCs in primary culture were treated with the LRP1 ligand, tPA. Within 5 min, ERK1/2 was activated ( Fig. 1a ), as anticipated [15] . Robust c-Jun phosphorylation was also observed in the same timeframe. To confirm that c-Jun phosphorylation by tPA requires LRP1, we added the LRP1 cell-signaling antagonist, RAP. In the absence of tPA, RAP exerted no effect on c-Jun phosphorylation or ERK1/2 activation. When RAP was added together with tPA, ERK1/2 activation and c-Jun phosphorylation in response to tPA were blocked (Fig. 1a ).
Next, we tested the ability of a second LRP1 ligand, PEX, to induce c-Jun phosphorylation in cultured rat SCs. PEX includes the LRP1-binding motif in MMP-9, but lacks the protease active site [7, 16] . Figure 1b shows that PEX induced c-Jun phosphorylation and ERK1/2 activation similar to tPA (Fig. 1b) . Time-course experiments for the PEX response are shown in Fig. 1c . Importantly, RAP blocked c-Jun phosphorylation in response to PEX (Fig. 1c) .
LRP1 ligands activate c-Jun in human SCs
LRP1 has not been studied previously in human SCs. We identified LRP1 in cultured human SCs by immunoblot analysis using a species cross-reactive antibody that detects the 85 kDa LRP1 light chain (Fig. 2a) . The abundance of LRP1 in human SCs was similar to that detected in cultured rat SCs.
When PEX was incubated with cultured human SCs for 5-30 min, c-Jun was phosphorylated and ERK1/2 was activated ( Fig. 2b) . Both cell-signaling events appeared to occur concurrently. When human SCs were pretreated with RAP, c-Jun phosphorylation and ERK1/2 activation were blocked. These results show that the ability of LRP1 to activate c-Jun is conserved in rat and human SCs.
LRP1 ligands activate c-Jun in SCs in vivo
To test whether LRP1 promotes c-Jun phosphorylation in injured sciatic nerves in vivo, we injected tPA (12 µM), PEX (20 µM), or vehicle directly into crush-injured rat sciatic nerves. Injections were performed 24 h after crush injury when LRP1 expression is considerably upregulated in SCs [5, 17] . Nerve tissue 0-3 mm distal to the injury site was collected 15 min after injection. Immunoblot analysis showed a significant increase in c-Jun phosphorylation in nerves injected with either tPA (P < 0.05) or PEX (P < 0.01) compared with vehicletreated controls (Fig. 3a and b) . c-Jun phosphorylation was not observed in contralateral nerves.
The absence of detectable c-Jun phosphorylation in vehicle-injected, crush-injured nerves may have reflected the short exposure times that we used to demonstrate the robust response to PEX. Our protocol was not designed to detect changes in baseline cell signaling (compared with the contralateral nerve). We did observe an increase in total c-Jun in vivo after injection of tPA or PEX (Fig. 3a) . This is consistent with previous reports showing rapid upregulation of c-Jun protein expression by trophic factors [18] .
In addition to c-Jun phosphorylation, ERK1/2 activation was observed in crush-injured sciatic nerves in response to LRP1 ligands (Fig. 3a) , as anticipated [7, 15] . The increase in phosphorylated (activated) ERK1/2 was similar when tPA or PEX was injected (Fig. 3c ). Next, we performed dual-labeling IF microscopy to detect phosphorylated c-Jun and the compact myelin marker, P0, in PEX-treated crush-injured sciatic nerves. As controls, we also studied vehicle-injected crush-injured nerves and contralateral nerves. IF microscopy showed abundant phosphorylated c-Jun localized mainly to the SC nuclei in PEX-treated nerves (Fig. 3d ). Little to no c-Jun phosphorylation was detected in the vehicle-treated or contralateral sciatic nerve. Collectively, these findings indicate that c-Jun activation is regulated by SC LRP1 in vivo.
Discussion
Normal SC function and activation of the SC repair program are key in facilitating functional recovery from PNS injury and in preventing neuropathic pain [1, 19] . The transformation in the SC phenotype, associated with activation of the repair program, is profound. Changes in the SC mRNA transcriptome have been identified. Considerable information is available on the cellsignaling factors in SCs that are activated to execute the repair program. The transcription factor c-Jun plays a central role in this process, but is supported by other factors such as ERK1/2, which may be particularly important in regulating the expression of inflammatory mediators by SCs in PNS injury [20] [21] [22] [23] . Cultures were pretreated with receptor-associated protein (RAP) (300 nM) or vehicle as indicated. Equal amounts of cellular protein (15 µg) were loaded into each lane and subjected to SDS-PAGE and electrotransferred to nitrocellulose membranes. β-Actin and total ERK1/2 were determined as loading controls. Each blot represents at least two to three independent experiments. An important gap in our understanding of the SC repair program is the SC receptor that senses nerve injury and triggers the injury response. The current study was predicated on the hypothesis that LRP1 is that missing receptor. When we initiated the current study, abundant data were already available to support this hypothesis. First, LRP1 is upregulated rapidly in SCs in vivo in nerve injury and capable of activating ERK1/2 [5, 7] . Activation of LRP1-dependent cell-signaling induces expression of monocyte chemoattractant protein 1 (MCP-1/CCL2), a central chemokine involved in the recruitment of inflammatory cells to the injured PNS [11] . Furthermore, LRP1 possesses an unusually broad and diverse set of ligands, which remains incompletely characterized, but includes proteins released after PNS injury, in degenerated myelin, and from injured and dying cells [10, 13] . These characteristics position LRP1 favorably to function as an injury response receptor.
We have now shown that ligand binding to LRP1 activates c-Jun, a central event in activation of the SC repair program. This is consistent with previous reports showing that LRP1 modulates c-Jun signaling cascades in other cell types [24] . c-Jun activation was observed in both rat and human SCs in culture and in SCs in vivo in crushinjured rat sciatic nerves. The ability of LRP1 to trigger c-Jun phosphorylation in conjunction with ERK1/2 activation supports the hypothesis that LRP1 is a key injurydetection receptor in SCs in the PNS.
If LRP1 and c-Jun function as components of a single system in activation of the SC repair program, then one might assume that conditional deletion of either gene in SCs in mice would generate similar phenotypes. This is not the case. Mice with conditional c-Jun deletion in SCs experience slower myelin degeneration in PNS injury, unlike mice in which LRP1 is deleted in SCs, which show accelerated myelin degeneration. We believe that this difference reflects the activity of LRP1 in SC viability. In LRP1-deficient SCs, accelerated demyelination following nerve injury is not viewed as resulting from activation of the SC repair program, but instead, compromise to the health and function of SCs. Irrespective of whether this hypothesis is correct, our present results highlight the principle that loss-of-function model systems may not model the function of a gene protein when that gene protein is expressed, especially for a protein as complicated as LRP1, which works in conjunction with a family of ligands and co-receptors [12] . This is, however, an unresolved problem that may be best tackled by comparing the mRNA transcriptomes of LRP1-deficient SCs with those of SCs in which the repair program is activated and immature SC precursors in developing nerves. The latter two transcriptomes are not equivalent [25] .
Conclusion
We have shown that binding of ligands to LRP1 in SCs results in activation of c-Jun. In the context of previous results of the function of SC LRP1, our results support a model in which LRP1 functions as an injury-detection receptor in SCs.
